Harmine Hydrochloride Capsules for Diabetes Mellitus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Depression and Anxiety Center, New York, NY
Diabetes Mellitus
Harmine Hydrochloride Capsules - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: end of study, at 18 months

Month 18
Dose Limiting Toxicity (DLT)
Visual Analog Scale (VAS)

Trial Safety

Trial Design

1 Treatment Group

Harmine Dose
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Harmine Hydrochloride Capsules · No Placebo Group · Phase 1

Harmine Dose
Drug
Experimental Group · 1 Intervention: Harmine Hydrochloride Capsules · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: end of study, at 18 months
Closest Location: Depression and Anxiety Center · New York, NY
Photo of New York  1Photo of New York  2Photo of New York  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Diabetes Mellitus
0 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be able to understand the English language.
You are of childbearing potential and you are using an acceptable method of contraception to avoid pregnancy throughout the study as judged by the investigator.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.